We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ('Tandem"#{174}; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0%
currently the most widely used laboratory test in diagnosis and management of prostatic cancer. 2 Although extensive efforts have been made to improve the clinical performance of PAP assays, either by modifying the reagents in assays of enzymatic activity or by developing iminunoassays to measure the mass concentration of PAP, these efforts have not allowed earlier detection of the disease in a substantial proportion of patients tested (2) .
Recently, a new prostate-specific protein antigen (PSA) has been isolated and identified from prostatic epithelial cells and detected in sera from patients with prostatic cancer (6). PSA is physically, chemically, and immunologically distinct from prostatic acid phosphatase. It is a glycoprotein with a molecular mass of approximately 33 kDa. Normal, hyperplastic, and neoplastic prostatic tissues contain similar concentrations of PSA. It is not detectable (with current assays) in serum from women. Serum from patients with advanced prostatic cancer consistently contain increased concentrations of PSA as compared with serum from normal men (7) .
PSA is highly immunogenic, and immunoassays have been developed involving either polyclonal antibodies (7-9) or monoclonal antibodies (10-12) with use of either radioisotopes or enzymes as labels for either antigen or antibody.
Here we compare two immunoradiometric assays in which monoclonal antibodies are used-one for PAP (M-PAP) and the other for PSA-with a conventional assay for PAP based upon catalytic activity (E-PAP) in normal subjects and in men with a variety of prostatic diseases (primarily benign prostatic hyperplasia and prostatic adenocarcinoma). We included patients with earlier stages (A and B) of prostatic cancer, who were candidates for radical prostatectomy, as study subjects for detailed evaluation of assay performance-both for efficiency of detection as well as effectiveness of monitoring for recurrence of disease. Specimens were collected into evacuated tubes without anticoagulants. Serum was separated and aliquots were stored at -20 #{176}C until analysis.
Assay for PSA. PSA in serum was measured by using a solid-phase, double-antibody immunoradiometric assay ("Thndem#{174}-R PSA"; Hybritech, Inc., La Jolla, CA 92121). A 50-zL sample was incubated simultaneously with one monoclonal antibody to PSA coated on a plastic bead and 200 ji.L of a solution containing another lssIlabeled monoclonal antibody (directed at a separate and distinct antigenic site on the PSA molecule). After a 2-h incubation at room temperature, the plastic bead and tube were washed with a solution containing detergent and sodium azide (3 g/L).
Radioactivity
bound to the plastic bead was then counted in a gamma counter.
Calibrators over the concentration range of 0 to 100 g of PSA per liter, as well as control materials, were supplied by the manufacturer. The entire assay sequence was performed in accordance with the manufacturer's written instructions. (14) . The reference interval specified (by the supplier) for this assay in healthy men is 0.8 U/L (97.5 percentile).
Results
Precision. Table 1 shows the precision of the assays for PSA and PAP.
Linearity.
The M-PSA assay curve was linear over the All patients with stages C and D of prostate cancer had abnormally high M-PSA concentrations in their serum; serum M-PAP and E-PAP were within the reference intervals in some of these patients. A significant percentage (83%, 40/48) of patients with stage B prostate cancer had increased serum M-PSA concentrations (using 2.8 ug/L as a decision level) with M-PAP and E-PAP results within their respective reference intervals. Although some patients (4/11, or 36%) with early stage-A prostate cancer had increased serum M-PSA concentrations, the majority did not. M-PAP and E-PAP results in this group of patients were within the reference interval. Approximately half (19 of 37) of patients with benign prostatic hypertrophy, however, had increased concentrations of PSA in serum but results for serum M-PAP and E-PAP that were within the reference intervals. Table 2 lists clinical sensitivity and specificity (15) for correct identification of all patients with prostatic cancer, for each of the three tests. Although the sensitivity of M-PSA was much higher than that of M-PAP and E-PAP, the specificity of M-PSA was lower than that for the tests for PAP, primarily because of the overlap of increased M-PSA concentrations in serum between results for patients with prostatic cancer and those with benign prostatic hypertrophy. 
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can be identified in samples of tissue from normal prostate and from prostate in cases of benign prostatic hyperplasia and adenocarcinoma of the prostate (6). The prevalence of both benign hyperplasia and adenocarcinoma of the prostate increases after the fifth decade of life, and the two conditions may occur together in the same patient.
Comparison of the upper limits of the reference interval, the cutoff points, or the decision levels for PSA used in different studies to classi& patients is complicated by the lack of a well-defined analytical standard material that could be used to evaluate the calibration differences among different immunoassays for PSA. Decision levels used to classilS' PSA results as increased have ranged from 1.8 ag/L (7) to 2.5 g/L (8) to 2.7 ig/L (9) to 4.0 g/L (11). Incorporation of "healthy" older men into the reference population may increase the number of subjects with subclinical or mildly symptomatic benign prostatic hypertrophy. Selecting a decision level for PSA concentrations in serum that will allow clinically accurate discrimination between benign prostatic hypertrophy and prostatic carcinoma has proved difficult. Kuriyama et al. (7) , using a decision level of 1.8 tgfL, found increased PSA in 68% of sera from subjects with BPH, compared with increased PSA in 63-77% of sera from patients with stages A-C of prostatic carcinoma. In contrast, Takeuchi et al. (8) found serum PSA concentrations above their selected decision level of 2.5 g/L in only 7% of patients with BPH. Using a radioimmunoassay for PSA and a decision level of 2.7 g/L, Liedtke and Batjer (9) noted increased PSA concentrations in 86% of sera from patients with BPH. (In the present study, we found 60% of BPH patients to have M-PSA concentrations above our decision level of 2.8 pg/L.) Considering the high prevalence of BPH in older men, the finding of increased serum PSA concentration in this age group is not specific for prostatic carcinoma.
The effects on clinical sensitivity and specificity of selecting differing decision levels are illustrated in Figure 3 , with receiver operating characteristic curves shown for PSA, M-PAP, and E-PAP. As the performance of a test improves, this curve (as plotted in Figure 3) will shift upwards and to the left as true-positive rates increase and false-positive rates decrease (16). Our data for the three assays performed on our study patients, soplotted, indicate that the assay for PSA performs "better" in the above sense than does either assay for PAP. The PSA assay, however, shows no clear change in the slope of the receiver operating characteristic curve at any specific decision level, unlike the receiver operating characteristic curves for M-PAP and E-PAP, which show such changes at decision levels of 3.0 pgfL and 0.8 U/L, respectively. We selected a decision level of 2.8 zg/L PSA for our analysis of data, recognizing that at that level a substantial portion of patients having BPH would be classified as having increased serum PSA concentrations (false positives).
Serum PSA concentrations are increased above the upper limits of assay reference intervals for most patients with prostatic carcinoma (7) (8) (9) , with greater increases noted for patients with more extensive disease (stages C and D). Our data showed M-PSA >2. M-PSA has a differentproblem of specificity: that caused by the overlap between results for patients with early stages of prostatic cancer and those for patients with BPH.
Because PSA is produced exclusively by the prostate, the decreasing concentration of PSA in serum after radical prostatectomy can be used to determine the presence of residual prostate tissue. Serum PSA higher than the predicted postoperative value correlates with subsequent recurrence of disease (18).
Measurement of PSA in serum is also useful in monitoring patients with previously diagnosed prostatic carcinoma for recurrence of disease. Killian et al. (19) found increased serum PSA concentrations in 24 of 26 patients an average of 12 months before recurrence was noted clinically.
In a subsequent study (20), these same authors reported PSA to be more sensitive than other serially measured markers (serum acid phosphatase, either prostatic or total, total alkaline phosphatase in serum, or the bone-derived isoenzyme of alkaline phosphatase in serum) in detecting early recurrence of prostatic cancer.
In addition to PSA, other protein markers have been immunologically identified that appear to be localized to the prostate.
One of these, y-seminoprotein, was originally identified in normal seminal plasma for forensic purposes and an enzyme immunoassay involving monoclonal antibodies to this antigen has been studied with sera from patients with prostatic cancer (22). PSA and )'-seminoprotein show some immunohistochemical similarities, and the two antigens both may be useful markers for progression of prostatic carcinoma (23) . At least two other prostate-specific These antigens, however, are also found in normal as well as malignant tissue (as is PSA), and no published reports evaluating their useas serum markers for prostatic carcinoma are as yet available.
In summary: we find a two-site inununoradiometric assay in which monoclonal antibodies to prostate-specific antigen (M-PSA) are used has good analytical precision, linearity, and sensitivity (limit of detection). Initial clinical evaluation indicated that serum M-PSA was more frequently increased in the earlier stages of prostatic carcinoma than were results of two different assays for PAP, one a traditional assay based upon enzyme activity and the other an immuneradiometric assay. Concentrations of PSA in serum of patients with benign prostatic hypertrophy appear to overlap those of patients with the earliest stage A of prostatic carcinoma, and the assay for M-PSA is not sufficiently specific clinically to use as a screening test for the diagnosis of prostatic cancer in its earliest asymptomatic stage. The clinical progression of prostatic cancer, however, was associated with increasing concentrations of M-PSA in serum. The assay may be most useful in monitoring patients for presence of residual disease after radical prostatectomy and for recurrence of disease after treatment.
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